CFG
EGRX

Citizens Financial Group’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Citizens Financial Group’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-101
Closed -$5K – 990
2020
Q2 		$5K Sell
101
-175
-63% -$8.73K ﹤0.01% 898
2020
Q1 		$13K Hold
276
– – ﹤0.01% 697
2019
Q4 		$17K Buy
+276
New +$16.5K ﹤0.01% 651

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citizens Financial Group's EGRX Position: Q3 2020 in Review

Citizens Financial Group sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2020, closing a stake of 101 shares — an estimated $5K sold.

Citizens Financial Group first reported a position in EGRX in Q4 2019 and held it in 3 quarters. The position peaked at $17K in Q4 2019. 171 funds tracked by Wall St. Rank hold EGRX as of Q3 2020.

  • Citizens Financial Group reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Citizens Financial Group sold 101 Eagle Pharmaceuticals, Inc. shares in Q3 2020, an estimated $5K.
  • Citizens Financial Group first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2019 and held it in 3 quarters.
  • Citizens Financial Group's Eagle Pharmaceuticals, Inc. position peaked at $17K in Q4 2019.
  • 171 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2020.

Based on Citizens Financial Group's 13F filing for Q3 2020, filed 12 Nov 2020.